Overall, PZ1–PZ6 are promising protein–protein interaction-guided anti-ZIKV peptide candidates with activity against early viral entry-associated events.
Abstract
Zika virus (ZIKV) remains a public health concern because of its association with neurological complications and congenital disease, yet no specific antiviral therapy has been approved. Since the envelope (E) protein mediates viral attachment and early entry-associated membrane events, it represents an attractive antiviral target. Here, we used a protein–protein interaction-guided strategy to design peptides to interfere with predicted interfaces between the ZIKV E protein and cellular receptors involved in attachment. After in silico filtering and preliminary screening, six peptides (PZ1–PZ6) were selected. These peptides showed heterogeneous physicochemical profiles, low cytotoxicity and hemolytic activity under the tested conditions, and docking-predicted interactions with functional E protein regions. In HTR-8/SVneo cells, antiviral activity depended on the timing of exposure, with greater reductions in infectious titers during co-treatment and post-treatment. All peptides also reduced titers in anti-adsorption assays, supporting interference with viral attachment or early entry-associated events. Consistently, DiOC18 fluorescence signals were reduced in a peptide-specific manner, particularly for PZ3 and PZ6. Nuclease protection assays showed no extensive exposure of the viral genome, whereas transmission electron microscopy revealed ultrastructural alterations without generalized particle disruption. Overall, PZ1–PZ6 are promising protein–protein interaction-guided anti-ZIKV peptide candidates with activity against early viral entry-associated events.
A comprehensive overview of ZIKV pathogenesis, transmission routes, and molecular mechanisms underlying host–virus interactions is provided, with emphasis on structural and functional insights into key viral enzymes NS2B–NS3 protease and NS5 RNA-dependent RNA polymerase which serve as pivotal antiviral drug targets.
Arvind Kumar, Harpreet Singh, Sagar Varshney et al.· Chemical biology letters· 0 citations
A rapid drug development platform that integrates covalent docking with direct-to-biology (D2B) synthesis and screening to identify nsP2 inhibitors is presented, which establish a streamlined strategy for covalent inhibitor development and provide promising leads for CHIKV antiviral development.
Zheng-Jun Cai, Kan Li, Sainetra Sridhar et al.· Journal of Medicinal Chemist...· 1 citation
It is demonstrated that genetically encoded, site-specific photo-crosslinking enables selective capture of transient interactions that are often missed by nonspecific 254 nm UV crosslinking approaches and highlights Orf3a as a multifunctional protein that engages diverse host pathways.
Eryn Lundrigan, Noreen Ahmed, J. P. Pezacki· Protein engineering, design...· 0 citations
The findings discussed in this review underscore the promise of eco-friendly nanotechnology as a sustainable and effective platform for developing next-generation antiviral therapies against dengue virus.
D. M. Kumar, R. Bharath, P. Venkataraman et al.· Viruses· 0 citations
Compound 13e exhibited potent antiviral efficacy, as evidenced by viremia quantification and histopathological analysis results, without causing significant body weight loss or other toxicities.
Dabeen Lim, Chanwoo Lee, Jihun Kim et al.· Bioorganic chemistry (Print)· 0 citations
Findings establish that both catalytic and allosteric sites play essential roles in regulating 3CL pro function, and targeting allosteric regions such as the Asn28-associated pocket offers a promising approach for antiviral development.
Unknown authors· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.